Fetching the paper…
Reading the bibliography…
Treatment switching in a randomized controlled trial is said to occur when a patient randomized to one treatment arm switches to another treatment arm during follow-up.
“The asymptotic properties of nonparametric tests for comparing survival distributions”
David Schoenfeld · 1981
Earlier work this paper cites.
“A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect”
James Robins · 1986
Earlier work this paper cites.
“A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods”
James Robins · 1987
Earlier work this paper cites.
“Correcting for non-compliance in randomized trials using rank preserving structural failure time models”
James Robins and Anastasios Tsiatis · 1991
Earlier work this paper cites.
“Adjusting for differential rates of prophylaxis therapy for PCP in high-versus low-dose AZT treatment arms in an AIDS randomized trial”
James Robins and Sander Greenland · 1994
Earlier work this paper cites.
“Weak convergence”
Aad Van and Jon Wellner · 1996
Earlier work this paper cites.
“Adjusting for non-compliance and contamination in randomized clinical trials”
Jack Cuzick, Robert Edwards and Nereo Segnan · 1997
Earlier work this paper cites.
“Semiparametric regression for the mean and rate functions of recurrent events”
Danyu Lin, Lee-Jen Wei, I Yang and Zhiliang Ying · 2000
Earlier work this paper cites.
“Marginal structural models versus structural nested models as tools for causal inference”
James Robins · 2000
Earlier work this paper cites.
“Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests”
James Robins and Dianne Finkelstein · 2000
Earlier work this paper cites.
“Asymptotic Statistics”
Aad Van · 2000
Earlier work this paper cites.
“Instrumental variables and the search for identification: from supply and demand to natural experiments”
Joshua Angrist and Alan Krueger · 2001
Earlier work this paper cites.
“Administrative and artificial censoring in censored regression models”
Marshall Joffe · 2001
Cited alongside, same era.
“‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?”
George Davey and Shah Ebrahim · 2003
Cited alongside, same era.
“Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects”
Takuhiro Yamaguchi and Yasuo Ohashi · 2003
Cited alongside, same era.
“Apolipoprotein E isoforms, serum cholesterol, and cancer”
Martjin Katan · 2004
Cited alongside, same era.
“Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial”
George Demetri, Allan van Oosterom, Christopher Garrett, Martin Blackstein, Manisha Shah, Jaap Verweij, Grant McArthur, Ian Judson, Michael Heinrich and Jeffrey Morgan · 2006
“HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial”
Karen Tashima, Laura Smeaton, Carl Fichtenbaum, Adriana Andrade, Joseph Eron, Rajesh Gandhi, Victoria Johnson, Karin Klingman, Justin Ritz and Sally Hodder · 2015
Later among the works it cites.
“Instrumental variable estimation in a survival context”
Eric. Tchetgen, Stefan Walter, Stijn Vansteelandt, Torben Martinussen and Maria Glymour · 2015
Later among the works it cites.
“Gaining power and precision by using model–based weights in the analysis of late stage cancer trials with substantial treatment switching”
Jack Bowden, Shaun Seaman, Xin Huang and Ian White · 2016
Later among the works it cites.
“Evaluating the effects of treatment switching with randomization as an instrumental variable in a randomized controlled trial”
Sara Jimenez, Dejian Lai, K Gould and Barry Davis · 2017
Later among the works it cites.
“Adjusting for treatment switching in randomised controlled trials–a simulation study and a simplified two-stage method”
alphaXiv searches the wider corpus for related work and actual follow-ups.
alphaXiv is searching for related work…
Cited alongside, same era.
“Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial”
Robert Motzer, Bernard Escudier, Stéphane Oudard, Thomas Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John Thompson, Robert Figlin and Norbert Hollaender · 2008
Cited alongside, same era.
“Econometric Analysis of Cross Section and Panel Data”
Jeffrey Wooldridge · 2010
Cited alongside, same era.
“Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study”
James Morden, Paul Lambert, Nicholas Latimer, Keith Abrams and Allan Wailoo · 2011
Cited alongside, same era.
“G-estimation and artificial censoring: problems, challenges, and applications”
Marshall Joffe, Wei Yang and Harold Feldman · 2012
Cited alongside, same era.
“Structural nested models and G-estimation: the partially realized promise”
Stijn Vansteelandt and Marshall Joffe · 2014
Cited alongside, same era.
“Instrumental variable additive hazards models”
Jialiang Li, Jason Fine and Alan Brookhart · 2015
Cited alongside, same era.
“Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race–ethnicity determine the degree of regimen complexity”
Karen Tashima, Katie Mollan, Lumine Na, Rajesh Gandhi, Karin Klingman, Carl Fichtenbaum, Adriana Andrade, Victoria Johnson, Joseph Eron and Laura Smeaton · 2015
Cited alongside, same era.
Nicholas Latimer, KR Abrams, PC Lambert, MJ Crowther, AJ Wailoo, JP Morden, RL Akehurst and MJ Campbell · 2017
Later among the works it cites.
“Instrumental variables estimation of exposure effects on a time-to-event endpoint using structural cumulative survival models”
Torben Martinussen, Stijn Vansteelandt, Eric. Tchetgen and David Zucker · 2017
Later among the works it cites.
“The GENIUS approach to robust Mendelian randomization inference”
Eric. Tchetgen, BaoLuo Sun and Stefan Walter · 2017
Later among the works it cites.
“Assessing methods for dealing with treatment switching in clinical trials: a follow-up simulation study”
Nicholas Latimer, Keith Abrams, Paul Lambert, James Morden and Michael Crowther · 2018
Later among the works it cites.
Andrew Ying, Ronghui Xu and James Murphy · 2019
Later among the works it cites.
“Adjusting for time-varying confounders in survival analysis using structural nested cumulative survival time models”
Shaun Seaman, Oliver Dukes, Ruth Keogh and Stijn Vansteelandt · 2020
Later among the works it cites.
“Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting”
Thomas Sullivan, Nicholas Latimer, Jodi Gray, Michael Sorich, Amy Salter and Jonathan Karnon · 2020
Later among the works it cites.
“ivsacim: Instrumental Variables Estimation Using Structural Additive Cumulative Intensity Models” R package version 1.1, 2021
Andrew Ying · 2021
Closest in time.